|
| Exchange Received Time 14/12/2017 09:09:29 Exchange Disseminated Time 14/12/2017 09:09:37 Time Taken 00:00:08 | December 14, 2017
Dear Sirs,
Sub: Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris™ in Patients with Perennial Allergic Rhinitis
With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.
Request you to kindly take the same on record.
Thanking you,
Yours faithfully,
For Glenmark Pharmaceuticals Limited
Harish Kuber
Company Secretary & Compliance Officer
|
|
|